YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys PTE Ltd., a...
View ArticleDaiichi Sankyo Starts Two Phase III Trials for Lung and Gastric Cancer
Singapore, May 2, 2013 – INNOMAb Pte Ltd is delighted to announce the start of patient recruitment into the phase III clinical trials has begun (http://www.daiichisankyo.com). Dr. Rikrik Ilyas, the CEO...
View ArticleNimotuzumab Phase IIB/IIIA Pancreatic Cancer Data to be presented at ASCO 2013
Singapore, May 17, 2013 – Dr. Dirk Strumberg (Germany) will be presenting nimotuzumab’s phase IIB/IIIA clinical trial data on advanced pancreatic cancer at 2013 ASCO Annual Meeting, Chicago. This study...
View Article
More Pages to Explore .....
